Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer - PubMed
3 hours ago
- #targeted therapy
- #clinical trial
- #breast cancer
- The VIKTORIA-1 trial evaluated gedatolisib plus fulvestrant with or without palbociclib in HR+/HER2-, PIK3CA wild-type advanced breast cancer.
- Results from the study were published in the Journal of Clinical Oncology in April 2026, indicating its clinical trial nature.
- The trial involved multiple researchers and study groups, highlighting a collaborative effort in investigating this treatment combination.